Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a heart drug be a new key to controlling high blood pressure?

NCT ID NCT06604897

Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This study looks at whether the medication Entresto (sacubitril/valsartan) helps Japanese patients with essential hypertension achieve blood pressure targets recommended by Japanese guidelines. Researchers will analyze electronic medical records from a large database, focusing on patients who started Entresto and tracking their blood pressure over several months. The goal is to see how many patients reach the desired systolic and diastolic blood pressure levels.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Sacubitril/valsartan (Entresto)
What this could lead to
If effective, this could support using Entresto as a treatment option for high blood pressure in Japanese patients.
What could go wrong
This is a retrospective database analysis, not a controlled trial, so results may be influenced by patient selection and missing data. It also focuses on a specific population, so findings may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,405 people

The number who actually took part.

Started

Jan 2023

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This is a retrospective, noninterventional cohort study.

Ages

20 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: 1. Diagnosed with essential hypertension (International Classification of Diseases \[ICD\]-10 code: I10) on the index date. 2. Patients for whom data for the 6 months prior to the index date can be extracted as baseline data. 3. Patients for whom blood pressure (BP) data can be extracted between weeks 8 and 12 after the index date. 4. Patients whose BP data can be extracted on the index date. 5. Patients whose BP value at baseline was 140/90 millimeters of mercury (mmHg) or higher. 6. Patients with the prescription of 100 milligrams (mg) or 200 mg once daily as 100 mg or 200 mg tablets on the index date. Exclusion criteria: 1. Women with a record of pregnancy-related diagnoses, drugs, or medical procedures before or after the index date, or a record of delivery- or abortion-related diagnoses, drugs, or medical procedures after the index date. 2. Prescription of concomitant angiotensin-converting enzyme inhibitor (ACEi); Anatomical Therapeutic Chemical (ATC) code: C09A on, after, or in the 2 days before the index date. 3. Patients diagnosed with angioedema: ICD-10: D84.1 under prescription of ACEi or angiotensin receptor blocker (ARB); ATC code: C09C. 4. Patients diagnosed with diabetes and under treatment with aliskiren fumarate on the index date. 5. Patients with severe impaired liver functions with Child-Pugh classification C.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Essential hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

essential hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Essential hypertension

Contacts and locations

Locations

  • Novartis

    East Hanover, New Jersey, 07936, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.